Orthocell (ASX:OCC) said interim results from a new study showed that nerve repair with the firm's Remplir nerve repair product resulted in superior regeneration of nerve tissue and earlier return of muscle function, compared to the current standard of care, according to a Thursday Australian bourse filing.
The study, commissioned by the firm to support the rollout of Remplir in the US, was evaluating the impact of sutures on nerve regeneration and functional recovery in the surgical repair of severed peripheral nerves.
The use of Remplir allowed surgeons to reduce the number of sutures required to reconnect severed nerves. The study was conducted using an established rat sciatic nerve injury model, and the repair of surgically severed nerves was evaluated in 48 rats across four treatment groups. The first group saw repair using one suture, the second one saw repair using three sutures, the third group saw repair using six sutures, and the fourth saw repair using one suture augmented with Remplir.
Nerve function and regeneration were evaluated up to 12 weeks post-treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。